Biora Therapeutics, Inc. BIOR
Mar 13, 2026, 9:30 AM EDT
- YTD
- 0.00%
- 1 year
- 0.00%
Discussion (14)
Sign in to join the discussion
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
$BI0R..?????
Gradoth — you imminent SOB
Wow look at the volume at 1pm?! 400k…. Big buyer?
Wow. The FUD! Trying hard here!!
$BIOR whoa! Type 2 diabetes treatment. That’s a much bigger population than Crone’s.
Rollin, rollin, rollin… keep them doggies rollin….
Time for loser trust funders to eat a fat one
